On September 25, 2013, the FDA issued a Drug Safety Communication announcing that the FDA has approved changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) to add new Boxed
Read More...
Read the complete post at http://feedproxy.google.com/~r/aids/gov/~3/9Fb9P2YLLOs/fda-safety-communication-reducing-the-risk-of-hepatitis-b-reactivation-in-patients-using-two-immune-suppressing-and-anti-cancer-drugs.html
Posted
Oct 21 2013, 09:30 AM
by
AIDS.gov blog